Seeking reliable markers to predict chemotherapeutic efficacy in advanced esophagogastric cancer, tumour tissues from 72 patients from the collective of the FLO vs. FLP phase III study of the AIO were tested for expression of VEGFR-3 and CXCR4. This evidence concerns the gene FLT4 and neoplasm.